Skip to main content

Table 3 The exact situations in which biologics were utilized for JDM. Respondents could answer more than one time. Ten potential respondents did not choose any of the choices

From: Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America

After failing mtx 5/94 5.3%
After failing CS and mtx 14/94 14.9%
After failing CS, mtx, and IVIG 39/94 41.5%
After failing CS, mtx, IVIG, or IM (AZA, MMF, or CSA) 48/94 51.1%
Systemic JDM with internal organ involvement 10/94 14.9%
Severe ulcerative disease 14/94 14.9%
Other 27/94 14.9%
  1. Abbreviations: mtx oral, subcutaneous, or intravenous methotrexate, CS oral or intravenous corticosteroids, AZA azathioprine, MMF mycophenolate, CSA cyclosporine A